Dashboard
Recursion Pharmaceuticals, Inc.
RXRXNASDAQFor informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.
Universal block
Live market data + trailing fundamentals.
Recent events
Material filings, federal awards, and regulatory activity. Impact is scored against market cap.
- Nov 20OtherClinicalTrials.gov
ClinicalTrials.gov update for NCT05985655 (GTAEXS617, Phase 1/2, advanced solid tumors): status changed to ACTIVE_NOT_RECRUITING; sponsored by Exscientia AI Ltd
- Nov 18Ownership changeSEC
Form 4 insider transaction filing.
- Nov 18Ownership changeSEC
Form 4 insider transaction filing reported.
- Nov 18Ownership changeSEC
Form 4 filing for change in beneficial ownership by insider at RXRX.
- Nov 4Ownership changeSEC
SEC Form 4 insider ownership change filing dated 2026-11-04.
- Nov 4Ownership changeSEC
SEC Form 4 insider ownership change filing.
- Nov 2Financial resultsSEC
8-K filing disclosing Q3 financial results (item 2.02) and leadership changes (item 5.02).
- Oct 15Securities offeringSEC
Recursion Pharmaceuticals filed Form 424B5 prospectus supplement.
- Oct 15OtherSEC
8-K filing covering items 1.01, 2.02, 7.01, 8.01, 9.01
- Oct 15Securities offeringSEC
Filed 424B5 prospectus supplement.
- Oct 7Ownership changeSEC
Form 4 insider ownership change filing dated 2026-10-07.
- Oct 7Ownership changeSEC
Form 4 insider transaction filing dated 2026-10-07.
- Oct 2Ownership changeSEC
Form 4 insider transaction filing.
- Oct 2Ownership changeSEC
SEC Form 4 insider transaction filing.
- Sep 21DealSEC
8-K item 1.01: entered into material definitive agreement.
- Sep 16Ownership changeSEC
Form 4 insider transaction filing.
- Sep 10Ownership changeSEC
Form 4 insider transaction filing.
- Sep 2Ownership changeSEC
Form 4 insider transaction filing.
- Aug 18Ownership changeSEC
Form 4 insider transaction filing.
- Aug 18Ownership changeSEC
Form 4 insider ownership change filing dated 2026-08-18.
Not financial advice — research and opinion only. Disclosures